NO20021625D0 - Synergistiske kombinasjoner av en NK1 reseptor antagonist og en GABA strukturell analog - Google Patents

Synergistiske kombinasjoner av en NK1 reseptor antagonist og en GABA strukturell analog

Info

Publication number
NO20021625D0
NO20021625D0 NO20021625A NO20021625A NO20021625D0 NO 20021625 D0 NO20021625 D0 NO 20021625D0 NO 20021625 A NO20021625 A NO 20021625A NO 20021625 A NO20021625 A NO 20021625A NO 20021625 D0 NO20021625 D0 NO 20021625D0
Authority
NO
Norway
Prior art keywords
receptor antagonist
synergistic combinations
structural analogue
gaba
gaba structural
Prior art date
Application number
NO20021625A
Other languages
English (en)
Norwegian (no)
Other versions
NO20021625L (no
Inventor
John Hughes
Lakhbir Singh
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20021625L publication Critical patent/NO20021625L/no
Publication of NO20021625D0 publication Critical patent/NO20021625D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20021625A 1999-10-07 2002-04-05 Synergistiske kombinasjoner av en NK1 reseptor antagonist og en GABA strukturell analog NO20021625D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15827199P 1999-10-07 1999-10-07
PCT/EP2000/009858 WO2001024792A1 (en) 1999-10-07 2000-10-05 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog

Publications (2)

Publication Number Publication Date
NO20021625L NO20021625L (no) 2002-04-05
NO20021625D0 true NO20021625D0 (no) 2002-04-05

Family

ID=22567369

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021625A NO20021625D0 (no) 1999-10-07 2002-04-05 Synergistiske kombinasjoner av en NK1 reseptor antagonist og en GABA strukturell analog

Country Status (38)

Country Link
EP (2) EP1221950B1 (de)
JP (2) JP2003510356A (de)
KR (1) KR20020060192A (de)
CN (1) CN1387434A (de)
AP (1) AP2002002501A0 (de)
AR (1) AR029646A1 (de)
AT (1) ATE269072T1 (de)
AU (2) AU7663300A (de)
BG (1) BG106548A (de)
BR (1) BR0014598A (de)
CA (1) CA2385930A1 (de)
CO (1) CO5280195A1 (de)
CR (1) CR6614A (de)
CZ (1) CZ20021116A3 (de)
DE (1) DE60011650T2 (de)
DK (1) DK1221950T3 (de)
EA (1) EA004266B1 (de)
EE (1) EE200200185A (de)
ES (1) ES2220542T3 (de)
GT (1) GT200000166A (de)
HR (1) HRP20020286A2 (de)
HU (1) HUP0203466A3 (de)
IL (1) IL148965A0 (de)
IS (1) IS6318A (de)
MA (1) MA26826A1 (de)
MX (1) MXPA02003484A (de)
NO (1) NO20021625D0 (de)
NZ (1) NZ517949A (de)
OA (1) OA12063A (de)
PA (1) PA8504301A1 (de)
PE (1) PE20010708A1 (de)
PL (1) PL357498A1 (de)
PT (1) PT1221950E (de)
SK (1) SK4542002A3 (de)
TR (1) TR200200913T2 (de)
UY (1) UY26376A1 (de)
WO (2) WO2001024792A1 (de)
ZA (1) ZA200202675B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US20030232805A1 (en) * 2002-04-24 2003-12-18 Cypress Bioscience, Inc. Prevention and treatment of functional somatic disorders, including stress-related disorders
AU2003267732A1 (en) * 2002-10-08 2004-05-04 Ranbaxy Laboratories Limited Gabapentin tablets and methods for their preparation
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
DE602004003172T2 (de) * 2003-03-21 2007-09-27 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
EP1543831A1 (de) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Zusammensetzung enthaltend Pregabalin
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
CA2805371C (en) 2010-07-30 2017-10-31 Toray Industries, Inc. Therapeutic agent or prophylactic agent for neuropathic pain
WO2012050907A2 (en) * 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
DK3946260T3 (da) * 2019-03-26 2026-03-23 Orion Corp Pregabalinformuleringer og anvendelse deraf
WO2022234110A1 (en) * 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
DE69736390T2 (de) * 1996-10-07 2007-07-26 Merck Sharp & Dohme Ltd., Hoddesdon Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
EP0942734A1 (de) * 1996-12-02 1999-09-22 MERCK SHARP & DOHME LTD. Die verwendung von nk-1 rezeptor antagonisten für die behandlung von schweren sorge störungen

Also Published As

Publication number Publication date
WO2001024792A9 (en) 2002-09-06
ZA200202675B (en) 2003-04-15
IL148965A0 (en) 2002-11-10
NO20021625L (no) 2002-04-05
CA2385930A1 (en) 2001-04-12
EE200200185A (et) 2003-04-15
WO2001024791A1 (en) 2001-04-12
JP2003510355A (ja) 2003-03-18
WO2001024792A1 (en) 2001-04-12
TR200200913T2 (tr) 2002-09-23
DE60011650D1 (de) 2004-07-22
CN1387434A (zh) 2002-12-25
KR20020060192A (ko) 2002-07-16
OA12063A (en) 2006-05-03
EP1221950A1 (de) 2002-07-17
AU7663300A (en) 2001-05-10
SK4542002A3 (en) 2003-09-11
HRP20020286A2 (en) 2003-08-31
BG106548A (en) 2002-12-29
CZ20021116A3 (cs) 2003-05-14
JP2003510356A (ja) 2003-03-18
EP1221950B1 (de) 2004-06-16
AP2002002501A0 (en) 2002-06-30
ATE269072T1 (de) 2004-07-15
HUP0203466A3 (en) 2005-03-29
CR6614A (es) 2003-12-04
ES2220542T3 (es) 2004-12-16
CO5280195A1 (es) 2003-05-30
PA8504301A1 (es) 2002-08-26
UY26376A1 (es) 2000-12-29
IS6318A (is) 2002-03-21
NZ517949A (en) 2003-08-29
AR029646A1 (es) 2003-07-10
GT200000166A (es) 2002-03-30
BR0014598A (pt) 2002-06-11
PE20010708A1 (es) 2001-07-27
HUP0203466A2 (hu) 2003-02-28
MA26826A1 (fr) 2004-12-20
EP1233766A1 (de) 2002-08-28
PL357498A1 (en) 2004-07-26
AU1696201A (en) 2001-05-10
DK1221950T3 (da) 2004-09-20
DE60011650T2 (de) 2005-07-14
MXPA02003484A (es) 2004-09-10
EA004266B1 (ru) 2004-02-26
PT1221950E (pt) 2004-08-31
EA200200303A1 (ru) 2002-08-29

Similar Documents

Publication Publication Date Title
NO20021625D0 (no) Synergistiske kombinasjoner av en NK1 reseptor antagonist og en GABA strukturell analog
ID18579A (id) Analog indazol tersubstitusi
NO20000847D0 (no) Elastiske brønnsementsammensetninger og fremgangsmåter
IL98055A0 (en) Synergistic therapeutic compositions and methods comprising a renin inhibitor and/or an angiotensin i converting enzyme inhibitor and/or an angiotensin ii antagonist
EP1543034A4 (de) Behandlung und prophylaxe mit 4-1bb-bindenden mitteln
ATE321784T1 (de) Pthrp analogen
NO20022645D0 (no) Farmasöytisk superdisintegrerende stoff
EP1210371A4 (de) Cytokinrezeptor gamma-ähnliche kette
FI951300A7 (fi) Alfutsosiinihydrokloridin hitaan vapautumisen galeenisia muotoja
NO20002526L (no) Mellomprodukt med høyt legemiddelinnhold og orale doseringspreparater med modifisert frigivelse samt fremgangsmÕter for fremstilling derav
DE69815542D1 (de) Synergitische herbizide verfahren und zusammensetzungen
IT1293832B1 (it) Impianto dentale osteointegrato
ATE283687T1 (de) Rapamycin-formulierungen zur oralen verabreichung
FR2772272B1 (fr) Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
DK0884054T3 (da) Fastdosiskombination af en angiotensin-omdannende enzyminhibitor og en calsiumkanalantagonist til behandling af cardiovaskulære sygdomme
DK1173172T3 (da) Synergistiske virkninger af amlodipin og den hydroxylerede metabolit af atorvastatin
ITBS970011A0 (it) Inferriata componibile modularmente ed amovibile
IT1291652B1 (it) Composizioni farmaceutiche a copertura terapeutica programmata
TW488545U (en) Digital/analog waveform generator which can adjust bias automatically
ITMI20000129V0 (it) Struttura di ancoraggio per protesi odontoiatriche su impianti endo-ossei
FI19991789A7 (fi) Uunirakenteen arinajärjestely ja siihen liittyvä menetelmä
DK199900093U3 (da) Hurtigtvirkende kunstig muskel
TW391248U (en) Vise of a pontic gypsum cast
FI990952A0 (fi) Hammasimplantti

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application